Table 2.
Results of fixed-effect network meta-analysis and comparison with previous network meta-analysis by Rodgers et al., 2011[16]
| Placebo | Adalimumab 40 mg/2 weeks | Infliximab 5 mg/kg/8 weeks | Golimumab 50 kg/4 weeks | Etanercept 2x25 mg/week | ||
|---|---|---|---|---|---|---|
| PsARC response: |
Odds ratio versus placebo OR (95% CrI) |
NA |
4.28 (2.83, 6.57)† |
9.97 (5.95, 17.08)† |
10.33 (5.84, 19.04)† |
7.74 (4.5, 13.67)† |
| Probability (95% CrI)+ |
0.26 (0.22, 0.29) |
0.59 (0.48, 0.70) |
0.77 (0.66, 0.86) |
0.78 (0.66, 0.87) |
0.73 (0.60, 0.83) |
|
| Comparison with Rodgers 2011 [12] |
0.25 (0.18, 0.32) |
0.59 (0.44, 0.71) |
0.80 (0.67, 0.89) |
NA |
0.71 (0.57, 0.83) |
|
| Change in HAQ conditional on PsARC response |
WMD versus placebo non-responders | PsARC responders (95% CrI)* |
-0.26 (-0.32, -0.21)† |
-0.49 (-0.58, -0.40)† |
-0.66 (-0.77, -0.55)† |
-0.44 (-0.59, -0.29)† |
-0.64 (-0.77, -0.51)† |
| Comparison with Rodgers 2011 [12] |
-0.24 (-0.34, -0.15)† |
-0.48 (-0.60, -0.35)† |
-0.66 (-0.79, -0.52)† |
NA |
-0.63 (-0.81, -0.46)† |
|
| WMD versus placebo non-responders | PsARC non-responders (95% CrI)* |
NA |
-0.14 (-0.24, -0.03)† |
-0.20 (-0.31, -0.08)† |
-0.06 (-0.18, 0.06) |
-0.20 (-0.35, -0.050)† |
|
| |
Comparison with Rodgers 2011 [12] |
NA |
-0.13 (-0.26, -0.00)† |
-0.19 (-0.33, -0.06)† |
NA |
-0.19 (-0.381, 0.00) |
| PASI50 |
Probability (95% CrI)+ |
0.12 (0.09, 0.16) |
0.71 (0.51, 0.86) |
0.90 (0.80, 0.96) |
0.71 (0.50, 0.87) |
0.40 (0.16, 0.73) |
| |
Comparison with Rodgers 2011 [12] |
0.13 (0.09,0.18) |
0.74 (0.55,0.88) |
0.91 (0.82,0.97) |
NA |
0.40 (0.24,0.59) |
| PASI75 |
Probability (95% CrI)+ |
0.05 (0.03, 0.07) |
0.47 (0.27, 0.68) |
0.77 (0.59, 0.89) |
0.46 (0.26, 0.70) |
0.19 (0.06, 0.49) |
| |
Comparison with Rodgers 2011 [12] |
0.04 (0.03,0.07) |
0.48 (0.28,0.69) |
0.77 (0.59,0.90) |
NA |
0.18 (0.09,0.31) |
| PASI90 |
Probability (95% CrI)+ |
0.02 (0.01, 0.03) |
0.24 (0.12, 0.44) |
0.54 (0.34, 0.75) |
0.23 (0.11, 0.46) |
0.08 (0.02, 0.26) |
| Comparison with Rodgers 2011 [12] | 0.02 (0.01,0.03) | 0.26 (0.12,0.45) | 0.56 (0.35,0.77) | NA | 0.07 (0.03,0.15) |
CrI, credible interval (Bayesian probability interval); HAQ, health assessment questionnaire; NMA, network meta-analysis; OR, odds ratio; PsARC, Psoriatic Arthritis Response Criteria; PASI, Psoriasis Area and Severity Index; WMD, weighted mean differences; NA, not applicable †significant result based on 95% CrI. +Average results were used in the economic model; the probabilistic sensitivity analysis used a beta distribution. *Average results were used in the economic model; the probabilistic sensitivity analysis used a normal distribution. Results for direct, fixed-effect meta analysis for PASI 70/75/90 are reported in Additional files 6, 7 and 8.